TransMedics Group (NASDAQ:TMDX) Trading Up 9.7% on Analyst Upgrade

Posted by Brian Himes on Jun 18th, 2026

Shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) were up 9.7% on Thursday after Stifel Nicolaus raised their price target on the stock from $75.00 to $80.00. Stifel Nicolaus currently has a hold rating on the stock. TransMedics Group traded as high as $79.74 and last traded at $80.2980. Approximately 447,649 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 1,084,531 shares. The stock had previously closed at $73.22.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Canaccord Genuity Group lowered their price objective on TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Piper Sandler lowered their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. TD Cowen lowered their price objective on TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. increased their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $134.50.

Check Out Our Latest Research Report on TMDX

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TMDX. Militia Capital Management LLC bought a new stake in TransMedics Group in the first quarter valued at about $2,088,000. Janus Henderson Group PLC increased its holdings in TransMedics Group by 2.1% in the first quarter. Janus Henderson Group PLC now owns 73,488 shares of the company’s stock valued at $7,306,000 after purchasing an additional 1,537 shares during the last quarter. Amundi increased its holdings in TransMedics Group by 31.2% in the first quarter. Amundi now owns 6,897 shares of the company’s stock valued at $686,000 after purchasing an additional 1,640 shares during the last quarter. California State Teachers Retirement System increased its holdings in TransMedics Group by 22.8% in the first quarter. California State Teachers Retirement System now owns 37,840 shares of the company’s stock valued at $3,762,000 after purchasing an additional 7,019 shares during the last quarter. Finally, Quantinno Capital Management LP increased its holdings in TransMedics Group by 197.9% in the first quarter. Quantinno Capital Management LP now owns 8,059 shares of the company’s stock valued at $801,000 after purchasing an additional 5,354 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 9.2%

The firm has a fifty day simple moving average of $84.57 and a 200-day simple moving average of $113.51. The company has a market capitalization of $2.76 billion, a P/E ratio of 18.23 and a beta of 1.91. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.TransMedics Group’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter last year, the company posted $0.70 EPS. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.